LoadingLoadingLoadingNet selling: insiders sold $1.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net selling.
Buys/Adds (1)
FMR LLC
$32.5M
added
Sells/Trims (2)
Millennium
$162.4M
trimmed
Squarepoint
$56.8M
trimmed
Top-trader positions in NBIX could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Jul 30, 2026
Period ending
Jun 30, 2026
Earnings per share
$1.96 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 23, 2026
EPS expected
$2.07 to $3.39
Revenue expected
23 analysts
Last 30 days
Split both ways
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 30, 2026 | $2.85 / $1.96Yahoo Finance | +45.44% beat | $959.0M No estimate | Unavailable |
| Mar 31, 2026 | May 5, 2026 | $1.94 / $1.70Yahoo Finance | +14.36% beat | $814.5M No estimate | Unavailable |
| Dec 31, 2025 | Feb 11, 2026 | $1.88 / $2.30Yahoo Finance | -18.13% miss | $805.5M No estimate | Unavailable |
| Sep 30, 2025 | Oct 28, 2025 | $2.17 / $2.07Yahoo Finance | +4.89% beat | $794.9M No estimate | Unavailable |
| Jun 30, 2025 | Jul 30, 2025 | $1.65 / $1.50Alpha Vantage | +10.00% beat | $687.5M No estimate | Unavailable |
| Mar 31, 2025 | May 5, 2025 | $0.70 / $1.09Alpha Vantage | -35.78% miss | $572.6M No estimate | Unavailable |
| Dec 31, 2024 | Feb 6, 2025 | $1.69 / $1.93Alpha Vantage | -12.44% miss | $627.7M No estimate | Unavailable |
| Sep 30, 2024 | Oct 30, 2024 | $1.81 / $1.82Alpha Vantage | -0.55% in line | $622.1M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $794.9M | $805.5M | $814.5M | $959.0M |
| Cost of what it sold | $14.0M | $17.6M | $13.8M | $23.2M |
| Gross profit | $780.9M | $787.9M | $800.7M | $935.8M |
| What it spent | ||||
| Research and development | $250.0M | $258.2M | $296.2M | $326.7M |
| Sales and admin | $291.6M | $301.8M | $318.5M | $439.7M |
| Other operating costs | — | $17.0M | — | $16.4M |
| Total operating expenses | $541.9M | $577.0M | $614.7M | $782.8M |
| What was left | ||||
| Operating profit | $239.0M | $210.9M | $186.0M | $153.0M |
| Interest on debt | — | — | — | $2.9M |
| Profit before tax | $291.8M | $239.4M | $246.8M | $162.2M |
| Tax | $82.3M | $85.7M | $48.9M | $17.8M |
| Net profit | $209.5M | $153.7M | $197.9M | $144.4M |
| EBITDA | $299.5M | $235.4M | $193.3M | $189.9M |
This stock's price action is mixed.
Trend
Mixed
55 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Needham keeps Buy target at USD 204.00 for Neurocrine Biosciences stock
BullishOct 20Neurocrine Biosciences starts Alzheimer's Phase 2 trial
Leans bullishOct 20Neurocrine starts phase 2 trial of Alzheimer’s drug candidate By Investing.com
BullishOct 20Neurocrine Biosciences starts Phase 2 trial of NBI-1117567 for mild to moderate Alzheimer's cognitive impairment
NeutralOct 20Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
BullishOct 20How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story
Leans bullishOct 18Needham sets USD 204.00 target for Neurocrine Biosciences stock
NeutralOct 17How New CRENESSITY Data At Neurocrine Biosciences Stock Has Changed Its Investment Story
Leans bullishOct 1733 macro signals shaping NBIX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
